Regeneron Pharmaceuticals Inc.

Robbins LLP Is Investigating Regeneron Pharmaceuticals, Inc. (REGN) Officials on Behalf of Shareholders

Robbins LLP are investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders. Regeneron Pharmaceuticals develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Skip to content